TDC
RXST icon

Thompson Davis & Co’s RxSight RXST Stock Holding History

Thompson Davis & Co’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,200
Closed -$257K – 144
2024
Q3 		$257K Hold
5,200
– – 0.19% 86
2024
Q2 		$313K Hold
5,200
– – 0.27% 69
2024
Q1 		$268K Sell
5,200
-50
-1% -$2.45K 0.18% 70
2023
Q4 		$212K Buy
+5,250
New +$154K 0.18% 70

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Thompson Davis & Co's RXST Position: Q4 2024 in Review

Thompson Davis & Co sold out of RxSight (RXST) in Q4 2024, closing a stake of 5,200 shares — an estimated $257K sold.

Thompson Davis & Co first reported a position in RXST in Q4 2023 and held it in 4 quarters. The position peaked at $313K in Q2 2024. 212 funds tracked by Wall St. Rank hold RXST as of Q4 2024.

  • Thompson Davis & Co reported no remaining RxSight position as of Q4 2024 after selling out during the quarter.
  • Thompson Davis & Co sold 5,200 RxSight shares in Q4 2024, an estimated $257K.
  • Thompson Davis & Co first reported a position in RxSight in Q4 2023 and held it in 4 quarters.
  • Thompson Davis & Co's RxSight position peaked at $313K in Q2 2024.
  • 212 funds tracked by Wall St. Rank held RxSight as of Q4 2024.

Based on Thompson Davis & Co's 13F filing for Q4 2024, filed 3 Feb 2025.